Worcester’s RXi Pharmaceuticals and Generex Biotechnology Corp. say that their research on the potential for cancer-fighting vaccines has yielded positive early results.
The two companies, along with Generex subsidiary Antigen Express Inc., have been using RXi’s RNAi technology to develop vaccines that could be used to treat disease by affecting the body’s immune responses.
The company said its tests show that the technology can silence certain genes in a type of stem cell. That may allow the cells to be converted into immune stimulants that could help fight cancer.
